The Global Bio-imaging Market is estimated to be valued at US$ 5.74 BN in 2024 and is expected to exhibit a CAGR of 15.% over the forecast period from 2024 to 2031.

Key Takeaways
Key players operating in the Global Bio-imaging Market are Bracco Imaging S.P.A, Bayer HealthCare Pharmaceuticals, Esaote S.p.A, Digirad Corporation, FONAR Corporation, GE Healthcare, Hologic Inc., Hitachi Medical Corporation, Lantheus Medical Imaging, Inc., Covidien Pharmaceuticals, Mindray Medical International Limited., Gamma Medica Inc., Samsung Medison Co., Ltd., and Philips Healthcare. Key players are focusing on product launches and enhancing their product portfolio to gain a competitive advantage in the market. For instance, in 2021, Philips launched Incisive CT imaging and intervention platform to transform radiology workflows.

The growing incidence of cancer, cardiovascular diseases, neurological disorders is fueling the demand for advanced bio-imaging modalities globally. Bio-imaging helps detect diseases in earlier stages and facilitate timely diagnosis and treatment. Furthermore, increasing investments by governments and private organizations in the healthcare sector promise Global Bio-imaging Market Size growth over the forecast period.

The global bio-imaging market is expanding rapidly with advancements in technology. Players are focusing on emerging economies for business expansion due to increasing healthcare expenditures. Further, rising awareness regarding benefits of early disease diagnosis will boost the bio-imaging market revenue in the coming years.

Get More Insights on Bio-Imaging Market